IgG antibodies to SARS-CoV-2 in asymptomatic blood donors at two time points in KarachiKarachi의 두 시점에서 무증상 헌혈자의 SARS-CoV-2에 대한 IgG 항체Article Published on 2022-08-242022-09-11 Journal: PLoS ONE [Category] SARS, 진단, 치료기술, [키워드] 95% CI ABO age antibody Antigen Asymptomatic blood donor Blood donors Blood Group Blood groups Cohort COVID-19 COVID-19 infections Donor donors enrolled Enrollment exposure to frequencies Frequency group groups healthy healthy blood donor IgG IgG antibodies IgG antibody IgG response IgG responses incidence of COVID-19 individual individuals Infection Karachi male material no significant difference not differ pandemic protective immunity Proteins provide RBD reactivity Receptor binding domain reported SARS-CoV-2 SARS-CoV-2 PCR testing seropositive Seropositivity Seroprevalence significant difference spike subject Symptom university were measured [DOI] 10.1371/journal.pone.0271259 PMC 바로가기 [Article Type] Article
Reinfection With Severe Acute Respiratory Syndrome Coronavirus 2 Among Previously Infected Healthcare Personnel and First Responders중증급성호흡기증후군 코로나바이러스 2로 이전에 감염된 의료진과 응급구조원 중 재감염Article Published on 2022-08-242022-09-11 Journal: Clinical Infectious Diseases: An Official Publicat [Category] SARS, 변종, [키워드] 95% CI 95% confidence interval acute respiratory syndrome acute respiratory syndrome coronavirus adjusted hazard ratio antibody association circulation coronavirus coronavirus 2 coronavirus disease Coronavirus disease 2019 COVID-19 defined exposure to first positive first responders hazard healthcare healthcare personnel household transmission Lower MOST New York City nursing home occurred participant Participants participated positive proportional hazards model Protective provided reduced Reinfection respiratory Responder Rhode Island risk SARS-CoV-2 SARS-CoV-2 test serology test seronegative seropositive seropositive participant seropositive participants Seropositivity serostatus Serosurvey severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 Spike protein tested variant virus virus test widespread with COVID-19 [DOI] 10.1093/cid/ciab952 PMC 바로가기 [Article Type] Article
Seroprevalence and longevity of SARS-CoV-2 nucleocapsid antigen-IgG among health care workers in a large COVID-19 public hospital in Saudi Arabia: A prospective cohort study사우디 아라비아의 대규모 COVID-19 공립 병원의 의료 종사자들 사이에서 SARS-CoV-2 뉴클레오캡시드 항원-IgG의 혈청 유병률 및 수명: 전향적 코호트 연구Article Published on 2022-08-122022-09-11 Journal: PLoS ONE [Category] SARS, 진단, 치료기술, 치료법, [키워드] 95% CI addition Anosmia Antigen association baseline being Cohort conducted cough COVID-19 COVID-19 infection detectable diagnosed with COVID-19 different time point eligible epidemiological Factors females Fever Follow-up group HCW HCWs Health care Health care worker health care workers hospital hypertension IgG Infection infection control Logistic regression Longevity media median median age multivariable logistic regression nucleocapsid antigen Nurse Nurses Odds ratio pandemic participated PCR physician platform positive presence of antibodies Prevalence proportion prospective cohort study recruited respiratory risk factor Risk factors SARS-CoV-2 IgG SARS-CoV-2 nucleocapsid Saudi Arabia Serological testing seropositive seropositive status Seropositivity Seroprevalence significantly social media statistically Symptom was used [DOI] 10.1371/journal.pone.0272818 PMC 바로가기 [Article Type] Article
Robust long-term immunity to SARS-CoV-2 in patients recovered from severe COVID-19 after interleukin-6 blockade인터루킨-6 차단 후 중증 COVID-19에서 회복된 환자에서 SARS-CoV-2에 대한 강력한 장기 면역Article Published on 2022-08-012022-09-11 Journal: EBioMedicine [Category] COVID19(2023년), SARS, 바이오마커, 진단, 치료법, [키워드] 1:1 Affect anti-IL-6 anti-IL-6 therapy anti-IL6 antibody Antibody responses blockade conducted COVID-19 Critical deleterious effect deleterious effects domain Effect evaluated Follow-up greater humoral IgG IgG antibody IL-6 IL-6 blockade Immunity incidence increase in Infection interferon interferon-γ interleukin interleukin-6 Interleukin-6 blockade Laboratory longitudinal cohort study magnitude median Neutralizing antibodies neutralizing antibody no increase Patient patients hospitalized patients with COVID-19 positive proportion Prospective protective immunity receiving Reinfection responded to vaccination response responses risk robust SARS-CoV-2 SARS-COV-2 infection Seropositivity severe COVID-19 Spain subject subjects T-cell T-cell immunity T-cell Response T-cell responses therapy Tocilizumab treated [DOI] 10.1016/j.ebiom.2022.104153 PMC 바로가기 [Article Type] Article
COVID-19 mRNA Vaccine in Patients With Lymphoid Malignancy or Anti-CD20 Antibody Therapy: A Systematic Review and Meta-Analysis림프성 악성종양 환자 또는 항-CD20 항체 치료 환자의 코로나19 mRNA 백신: 체계적인 검토 및 메타 분석Meta-Analysis Published on 2022-08-012022-09-11 Journal: Clinical lymphoma, myeloma & leukemia [Category] 치료제, [키워드] anti-CD20 antibody articles attenuate B-cell B-cell target therapy cellular response Cellular responses chronic lymphocytic leukemia CLL COVID-19 COVID-19 mRNA vaccine COVID-19 mRNA vaccines Effectiveness exhibited humoral Humoral and cellular responses Humoral response independent independent of individual leukemia Long-term follow-up Lymphocytic leukemia lymphoid lymphoma malignancies malignancy material Meta-analysis mRNA mRNA vaccine mRNA vaccines Myeloma Patient PROTECT registration number response to vaccination retrieved review risk risk ratio Seropositivity significantly subtype systematic review T cell T cell responses therapy These data vaccination Vaccine were used within 6 months [DOI] 10.1016/j.clml.2022.03.012 PMC 바로가기 [Article Type] Meta-Analysis
Awareness of SARS-CoV-2 Omicron Variant Infection Among Adults With Recent COVID-19 Seropositivity최근 COVID-19 혈청 양성 반응을 보인 성인의 SARS-CoV-2 오미크론 변이 감염에 대한 인식Article Published on 2022-08-012022-09-11 Journal: JAMA Network Open [Category] SARS, 변종, 진단, 치료법, [키워드] 95% CI accounted adjusted odds ratio age analyzed anti-Nucleocapsid IgG antibody Awareness Care Clinical characteristics cohort study common cold COVID-19 COVID-19 testing delta variant demographic and clinical characteristics demonstrated enrolled Evidence evidence of evidenced Health Health care individual Infection Los Angele Los Angeles median medical records multivariable analyses multivariable analysis new SARS-CoV-2 omicron outcome participant Patient prevalent recent reported Result SARS-CoV-2 SARS-COV-2 infection Seroconversion serological serological evidence Seropositivity subsequent Symptoms the SARS-CoV-2 Transmission variant virus were infected women [DOI] 10.1001/jamanetworkopen.2022.27241 PMC 바로가기 [Article Type] Article
Severe acute respiratory syndrome coronavirus 2 antibody prevalence in adult patients with short bowel syndrome-A German multicenter cross-sectional study성인 단장증후군 환자에서 중증급성호흡기증후군 코로나바이러스 2 항체 유병률-독일 다기관 횡단면 연구Multicenter Study Published on 2022-08-012022-09-11 Journal: JPEN. Journal of parenteral and enteral nutrition [Category] COVID19(2023년), MERS, SARS, 진단, 치료법, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 antibody Antibody test Antigen asked assumed avoidance bowel Care comparable complexity concerning Contact contact with coronavirus coronavirus disease Coronavirus disease 2019 Course COVID-19 COVID-19 disease COVID-19 infection cross-sectional Definition disease Economy Effect fill out Frequency Germany group Hospitalized increased risk Infection less median Mild multicenter N protein National no difference nucleocapsid parenteral nutrition Patient patients positive Prevalence questionnaire receiving respiratory risk risk behavior risk factor SARS-CoV-2 SARS-CoV-2 antibodies SARS-CoV-2 antibody Seropositivity Seroprevalence severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 Short bowel syndrome short bowel syndrome (SBS). syndrome tertiary care center the patient Treatment [DOI] 10.1002/jpen.2410 PMC 바로가기 [Article Type] Multicenter Study
Antibody responses to the SARS-CoV-2 vaccines in hemodialysis patients: Is inactivated vaccine effective?혈액투석 환자에서 SARS-CoV-2 백신에 대한 항체 반응: 불활성화 백신이 효과적인가?Article Published on 2022-08-012022-09-11 Journal: Therapeutic apheresis and dialysis : official peer [Category] MERS, SARS, 진단, 치료기술, [키워드] antibody antibody level antibody levels Antibody Response carried Comparative control group COVID-19 detected antibody dose Effectiveness General population generate healthy volunteers Hemodialysis humoral Humoral response humoral responses immunization inactivated Inactivated vaccine investigated Maintenance hemodialysis mRNA mRNA vaccine mRNA vaccines Patient patients Receptor binding domain reduced SARS-CoV-2 SARS-CoV-2 spike protein SARS-CoV-2 vaccine SARS-CoV-2 vaccines Seropositivity significantly lower Spike protein symptomatic infection the SARS-CoV-2 Vaccine vaccine group Vaccines were measured while [DOI] 10.1111/1744-9987.13752 PMC 바로가기 [Article Type] Article
The kinetics and predictors of anti-SARS-CoV-2 antibodies up to 8 months after symptomatic COVID-19: A Czech cross-sectional studyCOVID-19 증상이 나타난 후 최대 8개월까지 항-SARS-CoV-2 항체의 동역학 및 예측인자: 체코 횡단 연구Article Published on 2022-08-012022-09-11 Journal: Journal of medical virology [Category] COVID19(2023년), SARS, 진단, 치료기술, 치료제, [키워드] 95% CI 95% confidence interval acute phase analyzed anti-SARS-CoV-2 antibody anti-SARS-CoV-2 IgG antibody Antibody responses average Course COVID-19 Cox regression model cross-sectional demonstrated determinant determinants HCW HCWs healthcare worker IgG IgG and IgM IgM Immunoglobulin indicate knowledge Neutralizing number of symptom Odds ratio prediction predictor Receptor-binding domain reported responses S1 and S2 SARS-CoV-2 SARS-CoV-2 detection SARS-CoV-2-specific antibodies SARS-CoV-2-specific antibody serology testing seropositive participant seropositive participants Seropositivity Seven specific antibodies Spike protein subsequent Symptom symptom duration symptom onset symptomatic tested the receptor-binding domain the spike protein time intervals was used [DOI] 10.1002/jmv.27784 PMC 바로가기 [Article Type] Article
High SARS-CoV-2 seroprevalence in Karaganda, Kazakhstan before the launch of COVID-19 vaccinationCOVID-19 예방 접종이 시작되기 전에 카자흐스탄 카라간다에서 높은 SARS-CoV-2 혈청 유병률Article Published on 2022-07-272022-09-11 Journal: PLoS ONE [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술, [키워드] 95% CI Administered Antibody-mediated immunity appear Asia asymptomatic subjects capture Clinical characteristics Cohort collected Continuous correlated COVID-19 COVID-19 transmission COVID-19 vaccination death demographic and clinical characteristics detect detectable effort IgA IgG Immunity Infection Kazakhstan mitigate nasopharyngeal swabs National pandemic participant PCR-negative performed positive Prevalence provide public health Questionnaires recruited reported respiratory Respiratory illness RT-qPCR SARS-CoV-2 SARS-CoV-2 seroprevalence serological assays serological surveillance Serologically Seropositivity subject subset Swab tested the antibodies thresholds titre vaccination Virus neutralization were used [DOI] 10.1371/journal.pone.0272008 PMC 바로가기 [Article Type] Article